載入中
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
前收盤價
US$3.77
+US$0.02 · +0.53%
盤中時間採用ET。市場資料可能有所延遲。
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$3.77
52週區間
目前US$3.77
盤中時間採用ET。市場資料可能有所延遲。
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
日內區間
目前US$3.77
52週區間
目前US$3.77
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 8000萬 USD | 280.5萬 USD | 634.2萬 USD | 1916.3萬 USD |
| 銷貨成本 | 139萬 USD | 6338.6萬 USD | 7180.1萬 USD | 7678.2萬 USD | 6970.1萬 USD |
| 毛利 | −139萬 USD | 1661.4萬 USD | −6899.6萬 USD | −7044萬 USD | −5053.8萬 USD |
| 研究與開發 | 5610.3萬 USD | 6338.6萬 USD | 7180.1萬 USD | 7678.2萬 USD | 6970.1萬 USD |
| 銷售、一般及管理費用 | 2866.6萬 USD | 3644.8萬 USD | 4166.8萬 USD | 4169.4萬 USD | 3051.6萬 USD |
| 營業費用 | 8337.9萬 USD | 3851.1萬 USD | 4166.8萬 USD | 4212.1萬 USD | 3051.6萬 USD |
| 利息收入 | — | — | — | — | 20.7萬 USD |
| 折舊和攤銷 | 139萬 USD | 159.3萬 USD | 217.2萬 USD | 241.4萬 USD | 251.5萬 USD |
| 營業利益 | −8476.9萬 USD | −2189.7萬 USD | −1.11億 USD | −1.13億 USD | −8105.4萬 USD |
| 淨利 | −7488萬 USD | −972.5萬 USD | −9733.5萬 USD | −1.1億 USD | −8084.7萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI806.92萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM666.86萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF215.26萬0.00%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB214.63萬0.02%108.2億 USD0.44%US$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM191.43萬0.03%64.1億 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO132.27萬0.01%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA122.95萬0.01%218.24億 USD0.03%US$32.79+0.40%
iShares Micro-Cap ETFIWC79.73萬0.06%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
